Table 3 Assessment of diagnostic accuracy and heterogeneity in subgroup analysis
From: Prognostic, diagnostic and clinicopathological roles of tsRNAs: a meta-analysis in breast cancer
Category | Number of studies | Sensitivity | Specificity | Positive Likelihood Ratio | Negative Likelihood Ratio | Diagnostic Odds Ratio | I2 (%) of DOR |
|---|---|---|---|---|---|---|---|
Total | 21 | 0.72 (0.71–0.74) | 0.64 (0.61–0.66) | 1.94 (1.76–2.12) | 0.44 (0.38–0.51) | 4.55 (3.67- 5.65) | 52.9 |
Country | |||||||
 China | 19 | 0.72 (0.71–0.74) | 0.63 (0.61–0.66) | 1.90 (1.74–2.07) | 0.45 (0.39–0.52) | 4.37 (3.51–5.44) | 53.3 |
 Japan | 2 | 0.73 (0.62–0.83) | 0.76 (0.65–0.86) | 3.02 (1.95–4.67) | 0.35 (0.24–0.52) | 8.70 (4.15–18.28) | 0.0 |
Expression | |||||||
 Down | 11 | 0.71 (0.68–0.73) | 0.65 (0.61–0.68) | 1.97 (1.68–2.31) | 0.45 (0.37–0.54) | 4.55 (3.22–6.43) | 62.9 |
 Up | 8 | 0.75 (0.72–0.77) | 0.64 (0.60–0.67) | 1.95 (1.75–2.18) | 0.41 (0.33–0.52) | 4.97 (3.77–6.56) | 40.7 |
 NA | 2 | 0.68 (0.57–0.77) | 0.55 (0.39–0.70) | 1.49 (1.05–2.12) | 0.60 (0.40–0.89) | 2.53 (1.21–5.32) | 0.0 |
Case | |||||||
  > 100 | 12 | 0.72 (0.70–0.74) | 0.63 (0.61–0.66) | 1.91 (1.72–2.12) | 0.45 (0.39–0.54) | 4.33 (3.40–5.50) | 59.7 |
  < 100 | 9 | 0.74 (0.69–0.78) | 0.66 (0.60–0.73) | 2.05 (1.65–2.54) | 0.41 (0.31–0.54) | 5.31 (3.29–8.57) | 44.0 |
Type | |||||||
 BCa | 10 | 0.75 (0.73–0.78) | 0.64 (0.60–0.67) | 1.96 (1.78–2.16) | 0.39 (0.32–0.49) | 5.23 (3.98–6.89) | 41.8 |
 EBCb | 6 | 0.69 (0.66–0.72) | 0.64 (0.61–0.68) | 1.94 (1.57–2.39) | 0.48 (0.39–0.60) | 4.08 (2.71–6.12) | 71.7 |
 NTNBCc | 5 | 0.71 (0.64–0.77) | 0.60 (0.50–0.69) | 1.70 (1.33–2.16) | 0.49 (0.35–0.69) | 3.59 (1.99–6.48) | 32.5 |